Gossamer Bio Finalizes Conversion & Warrant Prices for $181M Distressed Debt Exchange
GOSS sits 18% above its 52-week low of $0.14.
Summary
Gossamer Bio announced the initial conversion rate for its 2030 Convertible Notes and the exercise price for its Purchase Warrants, finalizing terms of its recent distressed debt exchange.
Key Events · Financing and Capital Events · GOSS
-
Conversion Rate Set for 2030 Convertible Notes
The initial conversion rate for the 7.50% Convertible Senior Secured First Lien Notes due 2030 is 5,347.5936 shares per $1,000 principal amount, representing a conversion price of approximately $0.19 per share.
-
Warrant Exercise Price Determined
The initial exercise price for the Purchase Warrants is set at $0.34 per whole share of common stock.
-
Finalizes Distressed Debt Exchange Terms
This announcement finalizes the pricing terms for the highly dilutive distressed debt exchange completed in June, which converted $181.05 million of existing convertible notes.
-
Pricing Relative to Market
The conversion price of $0.19 and warrant exercise price of $0.34 are set above the current stock price of $0.1652, based on a reference price of $0.17.
Analysis · GOSS · Life Sciences
This 8-K announces the specific conversion rate for the 2030 Convertible Notes and the exercise price for the Purchase Warrants, finalizing key terms of the distressed debt exchange completed in June. While the underlying debt exchange was highly dilutive and critical for the company's survival, setting the conversion price at $0.19 and the warrant exercise price at $0.34 (both above the current stock price of $0.1652) means that immediate conversion or exercise is not at a deep discount to the current market price. However, the potential for significant future dilution remains if the stock price rises above these levels, impacting existing shareholders.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 36.9% of the 1029 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GOSS was trading at $0.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $80.5M. The 52-week trading range was $0.14 to $3.87. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.